Abstract We performed a molecular study aimed at identifying a gene expression profile (GEP) signature predictive of attainment of at least near complete response (CR) to thalidomide-dexamethasone (TD) as induction regimen in preparation for double autologous stem cell transplantation in 112 younger patients with newly diagnosed multiple myeloma. A GEP supervised analysis was performed on a training set of 32 patients, allowing to identify 157 probe sets differentially expressed in patients with CR versus those failing CR to TD. We then generated an eight-gene GEP Electronic supplementary material The online version of this article (doi:10.1007/s00277-013-1757-6) contains supplementary material, which is available to authorized users. -013-1757-6 signature whose performance was subsequently validated in a training set of 80 patients. A correct prediction of response to TD was found in 71 % of the cases analyzed. The eight genes were downregulated in patients who achieved CR to TD. Comparisons between post-autotransplantation outcomes of the 44 non-CR-predicted patients and of the 36 CR-predicted patients showed that this latter subgroup had a statistically significant benefit in terms of higher rate of CR after autotransplant(s) and longer time to progression, eventfree survival, and overall survival. These results can be an important first step to identify at diagnosis those patients who will respond more favourably to a particular treatment strategy.
Introduction
In multiple myeloma (MM), genetic abnormalities of malignant plasma cells [1] [2] [3] [4] [5] markedly influence patient prognosis, which ranges from few months to more than 10 years. Genomic instability of the myeloma clone predisposes the patients to acquire recurrent numerical and structural chromosomal abnormalities. In the recent past, attempts have been made to more carefully analyze the prognostic value of these chromosomal changes. Results from several of these studies allowed to identify different subgroups of MM patients at different risk of death [1, 6] . These subgroups are characterized by the prevalence of a specific chromosomal abnormality, which ultimately results in the activation of particular bio-molecular pathways [7] [8] [9] [10] [11] [12] . More recently, the transcriptome of MM plasma cells has also been evaluated for its potential prognostic value [6, 13] . These analyses identified particular genetic signatures which were associated with more aggressive outcomes of the disease [14] [15] [16] . In addition, these studies demonstrated that high-throughput analysis of the tumor clone is highly important since underlying genetic changes drive different bio-molecular pathways which may be targeted by specific therapies.
Over the last few years, progress in the treatment of MM has been remarkable, mainly due to the widespread use of autologous stem cell transplantation (ASCT) and the recent availability of the novel agents thalidomide, bortezomib, and lenalidomide [17] . These drugs, initially investigated in refractory/relapsed phases of the disease, have been successfully used as part of upfront therapies for both younger and elderly myeloma patients [18] [19] [20] . In the transplant setting, incorporation of the novel agents into newer induction regimens has dramatically increased the rate of complete response (CR) or very good partial response before ASCT, a gain ultimately resulting in further improvement in highquality response rates following ASCT, prolonged eventfree survival (EFS), and overall survival (OS) [20] . Marked synergy between dexamethasone and thalidomide, the first agent with documented anti-myeloma activity since the introduction of melphalan and prednisone, provided the basis for the design of phase II "Bologna 2002" study incorporating thalidomide-dexamethasone (TD) into double ASCT as upfront therapy for newly diagnosed MM [21] .
Based on the recognition that the quality of response to induction therapy favorably affects outcomes of ASCT, we performed a retrospective molecular analysis aimed at developing and validating a gene expression profile signature predictive of attainment of CR, either immunofixation negative or positive (near CR, nCR) to induction therapy with TD. For this purpose, we generated gene expression data from a subgroup of patients who entered the study and then validated the results with real-time PCR analysis. The results of this study are herein reported.
Patients and methods

"Bologna 2002" study design
By study design, "Bologna 2002" trial comprised incorporation of TD into double ASCT for MM patients aged 65 years or less. Details of TD as induction therapy in preparation for ASCT have been described previously [22] . Briefly, thalidomide was administered orally at the dose of 200 mg/day, while pulsed dexamethasone, 40 mg/day on days 1 to 4, was given every 28 months; two additional courses of dexamethasone on days 9 to 12 and 17 to 20 were given on odd cycles. Following the induction phase, TD was continued until the second ASCT [21] .
Sample collection, enrichment, data generation, and quality control Bone marrow (BM) samples for molecular studies were obtained during standard diagnostic procedures. Written informed consent was obtained from each patient. Plasma cells were purified from mononuclear BM cells obtained by Ficoll-Hypaque density gradient centrifugation using anti-CD138 micro beads on an AutoMacs Magnetic Cell Separator (MACS system, Miltenyi Biotec, Auburn, CA). CD138+ cell fractions were than stored at −80°C in guanidium thiocyanate, until use. The purity of positively selected plasma cells was assessed by flow cytometry and was ≥90 % in all cases. Total RNA was obtained from each sample by the RNeasy® kit (Qiagen, Valencia, CA) extraction procedure: the RNeasy® Mini kit was used for more than 5× 10 5 cells, the RNeasy® Micro kit for less than 5×10 5 cells.
To measure concentration and purity of RNA, a NanoDrop ND-1000 spectrophotometer was used (NanoDrop Technologies, Wilmington, DE), which require only 1 μL of undiluted sample for assessment of concentration; purity of the extracted RNA was based on the 260/280 and the 260/230 O.D. ratios, as calculated and displayed by the NanoDrop spectrophotometer. Moreover, disposable RNA chips (Agilent RNA 6000 Nano LabChip kit) were used to determine the concentration and purity/integrity of RNA samples using Agilent 2100 Bioanalyzer. Samples with at least 30 ng/uL RNA were labelled for gene expression profiling, using the Affymetrix Two-cycles Gene Chip microarray system (Affymetrix, Santa Clara, CA). cDNA synthesis, biotin-labelled target synthesis, HG U133 Plus 2.0 GeneChip arrays hybridization, staining, and scanning were performed according to the standard protocol supplied by Affymetrix. For the purpose of the current study, BM samples were obtained from 112 out of 311 newly diagnosed MM who were enrolled in Bologna 2002 study. The first 32 cases (overall defined "training set") were successfully assayed for global gene expression, and microarray data were used to identify classifiers that predicted response to TD induction therapy. The results were then validated using the remaining 80 cases (overall defined "test set"). Gene expression array files are available for free download at http://www.ncbi.nlm.nih.gov (GEO, Gene Expression Omnibus), accession number GSE16791.
Response definition
Criteria for evaluating response to therapy were those previously reported by Bladè et al. [23] with the addition of a nCR category, as defined by the absence of M protein at routine electrophoresis but positivity of immunofixation. Evaluation of response to TD as induction therapy before ASCT(s) was performed after the planned 4 months of treatment. The best response achieved after double ASCT was considered in those patients who completed the entire treatment program. For patients who discontinued therapy, the best response ever achieved was evaluated. For the purposes of the present study, patients were categorized into two response groups, the first one including patients who actually attained CR or nCR (overall defined "responders" and labeled CR), the second one encompassing patients who failed at least nCR (overall defined "non-responders" and labeled NR).
Real-time quantitative PCR
cDNAs were reverse transcribed from total RNA samples (100 ng per sample) using the SuperscriptII® Reverse Transcriptase kit (Invitrogen Life Technologies, Carlsbad, CA), as described in the manufacturer's protocol. ABL gene (forward primer: 5′TCCTCCAGCTGTTATCTGGAAGA3′; reverse primer: 5′TGGGTCCAGCGAGAAGGTT3′) was amplified in all retrotranscribed samples, in order to exclude false negative samples from the analysis.
TaqMan PCR reactions were carried out from cDNA samples using custom TaqMan low-density arrays (Applied Biosystems, Foster City, CA, USA) by means of ABI PRISM 7900 HT Sequence Detection Systems: each array was designed to screen four patients at a time for the expression of ten genes and one control gene (GAPDH, glyceraldehyde-3-phosphate dehydrogenase), each performed in triplicate. The RealTime expression profile was achieved using the comparative Ct method of relative quantification.
Statistical analysis
To determine the differentially expressed genes between responders and non-responders, the Affymetrix output (CEL files) was imported into Genespring 7.3 microarray analysis software (Agilent Technologies), in which data files were normalized across chips using RMA and to the 50th percentile, followed by per gene normalization to the median. For the analysis, we only considered genes called present in at least 50 % of the patients from either group, resulting in a selection of 22,647 out of 54,675 probe sets. A one-way ANOVA test was applied to 413 out of the 22,647 probe sets, which shared a fold change ≥2, and a total of 157 probe sets (corresponding to 135 unique genes) were significantly associated to the TD response (P<0.05).
In order to obtain a smaller predictive set of genes, a Quadratic Discriminant Analysis (QDA), considering only the diagonal elements of the estimated covariance matrices, was performed on the training set, with a Leave-One-Out Cross-Validation procedure, considering several randomly chosen gene signatures (from eight to ten genes per signature). The performance of the optimal gene signature found was then tested on the validation set of 80 samples obtained by RT-qPCR.
The accuracy of the gene signature in predicting response to TD was expressed by the positive and negative predictive values (PPV and NNP, respectively). The PPV is calculated by dividing the number of true positive (TP) with the sum of TP and false positive (FP; e.g., TP/TP+FP). By the opposite, NNP is expressed by the ratio between true negative (TN) and the sum of TN and false negative (FN; e.g., TN/TN+ FN). In our context, TP identified those patients who were correctly CR-predicted, while FP identified CR-predicted patients who actually failed to attain CR. By contrast, TN patients were those correctly NR-predicted and FN identified NR-predicted patients who actually attained at least nCR. The sensitivity of the gene signature was defined as the proportion of correctly CR-predicted patients and was calculated as TP/TP+FN. The specificity was defined as the proportion of correctly NR-predicted patients and was calculated as TN/TN+FP.
Genes included in the signature were further analyzed for gene ontology (GO) classification by applying the DAVID tools (Database for Annotation, Visualization and Integrated Discovery) at the web address http://david.abcc.ncifcrf.gov, which characterizes genes based on defined categories of molecular function and biological processes. Results were ordered according to EASE score (which is a modified Fisher's exact test, the smaller the EASE score, the more significant the value) and according to the Enrichment Score (ES), which ranks the relative importance of the gene groups: a higher score indicates that the group members are involved in more important roles, even if all the gene groups are potentially interesting, despite lower ranking [24] . Data were also analyzed through the use of Ingenuity Pathway Analysis (IPA; Ingenuity® Systems, www.ingenuity.com), in order to get more insight into the relationships between gene products, on the basis of known interactions in the literature.
The Kaplan-Meier method was used to estimate EFS, OS, and time to progression (TTP). TTP and EFS were calculated from the start date of induction therapy to the date of progression (for TTP) or death for any cause, whichever occurred first (for EFS). OS was measured from the start date of induction therapy until death from any cause.
Results
Patient characteristics
One hundred and twelve patients out of 311 who were enrolled in Bologna 2002 study had selected CD138+ bone marrow plasma cells adequate for performing a gene expression analysis. Baseline clinical characteristics of these 112 patients were compared with those of the entire population of 311 patients. No statistically significant difference between the two groups was observed, suggesting that the 112 patients included in the genomic analysis were representative of the whole patient population ( Table 1) .
Determination of a Gene Signature predictive of the attainment of CR after TD induction therapy Gene expression profiles were generated using Affymetrix HG-U133 Plus 2.0 arrays from the 32 patients included in the training set. Firstly, unsupervised analysis was applied to these patients to assess whether responders (CR) could be differentiated from non-responders (NR). With this method, no clear separation between the two subgroups of patients was obtained (data not shown). To identify genes that were predictive of response to TD induction therapy, a one-way ANOVA test was used to directly compare patients achieving CR from those with less than at least nCR. Using this method, 157 probe sets, which were differentially expressed in CR vs. NR patients, were identified (P<0.05). Clustering of the expression profiles showed a homogeneous pattern of gene expression in those patients who achieved at least nCR: of the 157 probe sets identified, the majority (144 out of 157, or 91 %) were downregulated in CR patients. By contrast, only 13 probe sets (or 8.2 %) were overexpressed, showing a wide ratio of expression, with 3.17-to 101.6-fold increases in expression in CR patients, compared with NR patients (Supplementary Fig. S1 ).
The probe sets associated with response to TD represent genes of known function Down-and upregulated probe sets were analyzed employing the DAVID tools, and thus classified according to functional categories defined by GO. Chromosomes (chr.) 1 and 2 were the most significantly enriched in genes whose expression resulted in downregulation in responding patients: 22 out of 135 genes (17 %) were located on chr.1 (EASE score= 0.0019), 19 out of 135 genes (14.1 %) were located on chr.2 (EASE score=0.00083).
Downregulated genes
Overall, sufficient information was available for 126 downregulated genes. A Functional Annotation Cluster analysis of the 126 downregulated genes was applied with the highest classification stringency and generated 25 gene clusters, which code a wide range of functional gene categories. Supplementary Table 1 shows the top ten annotation clusters with a group ES greater than or equal to 0.05. The cluster related to apoptosis and cell death (11 genes, ES= 2.04), and the cluster related to cell development and differentiation (16 genes, ES=1.79) displayed the highest ES. In particular, the cluster related to apoptosis included the antiapoptotic factors XIAP/BIRC4, CFLAR, FAS, and Hspa1b, in addition to DLG5 (disc, large homolog 5), GAS2 (growtharrest specific 2), and MDM4, which are also involved in the negative regulation of cell proliferation, and to IFI16 and STAT1, which directly interact with the NF-kB pathway [25] [26] [27] [28] . Among genes involved in the regulation of transcription (19 genes, E.S. = 1.08), of note are ATF2, WHSC1/MMSET, MORF4L2 (which has been shown to predict response to chemotherapy in human colorectal tumors [29] ), and NCOA2/TIF2 (involved in chromosomal aberrations which have been shown to be associated with the development of acute myeloid leukemia [30] ). The observation that most of the abovementioned genes mapped to overlapping genetic networks generated by the IPA tools strongly suggests that they interact biologically. Indeed, five IPA networks were found to be significantly associated with hematological system development and function, immune response, protein degradation, and cancer among others (Supplementary Table 2 ).
Overexpressed genes
The nine identified genes that were notably overexpressed in CR patients were clustered into six functional clusters, the most significant of which are related to the immune response and the protein metabolism. Of particular interest is the overexpression of DUSP4 (dual specificity phosphatase 4) and of CADM1/IGSF4/TSLC1 (immunoglobulin superfamily member 4) in responding patients. DUSP4 is a member of the dual specificity protein phosphatase subfamily, which negatively regulates members of the mitogenactivated protein (MAP) kinase superfamily (MAPK/ERK, SAPK/JNK, p38). The overexpression of DUSP4 has been associated with the more benign phenotype of serous borderline tumor, as opposed to serous carcinoma, as a consequence of the suppression of ERK-dependent downstream regulation [31, 32] . CADM1/IGSF4/TSLC1 is a proapoptotic gene involved in cell-cell interactions. Loss of function of this tumor suppressor gene, localized on chromosome 11q23, has been shown to be involved in non-small cell lung cancer pathogenesis, through the interaction between its PDZ-binding-motif and a group of proteins belonging to the membrane-associated guanylate kinase homologs [33] .
Development of a GEP signature predictive of CR: an eight-gene classifier specifically predicts response to TD induction therapy Primary objective of the study was to obtain a small, manageable set of genes predictive of achievement of at least nCR to TD induction therapy. For this purpose, the expression data of the 157 probe sets obtained from the 32 profiled patients were further analyzed with a QDA classifier. This analysis was aimed at reducing the number of predictor genes while maintaining a high specificity and sensitivity in predicting the response. By testing several small subsets (including eight to ten probe sets) obtained from the 157 differentially expressed probe sets, we achieved the best performance with eight specific genes, which minimized the leave-one-out cross validation prediction error in the training set (Table 2 ). In fact, 31 out of 32 patients included in the training set were correctly classified, including all NR and five out of six CR patients. Principal component analysis was performed on the 32 patients with the eight-gene signature and demonstrated that responding patients were closely clustered, as opposed to NR patients who displayed a scattered distribution ( Supplementary Fig. S2 ). All of the eight genes which constitute the GEP signature (ATF2, CCND2, CFLAR, DDX17, HSPA1A, RIT1, RNF148, and WHSC1) were downregulated in responding patients. Of these, ATF2, CCND2, and RIT1 were the most significantly downregulated genes observed among the 157 probe sets associated with response to TD induction therapy. The eight genes do not appear to cluster in the human genome, although RIT1 and HSPA1A are both located on chr. 1q (cytoband 1q22 and 1q23, respectively), and ATF2 and CFLAR are both located on chr. 2q (cytoband 2q32 and 2q33-q34, respectively; Table 2 ). Six out of the eight genes (ATF2, CCND2, CFLAR, DDX17, HSPA1A, and RIT1) mapped to a genetic network, as generated by the IPA tool. Notably, the most important biological functions of these genes are cell cycle regulation, cellular organization, and drug metabolism. Of note, one of the most involved hubs of the network is represented by NF-kB, which directly interacts with both CFLAR and CCND2. These data suggest that downregulation of a subset of NF-kB targets characterizes myeloma cells more sensitive to TD therapy.
TaqMan low-density arrays successfully validate the eight-gene GEP signature predictive of CR to TD induction therapy on a test set of 80 patients
In the second part of the study, an external validation of the eight-gene GEP signature was performed in an independent real-time expression dataset. The eight-gene's expression data were obtained from CD138+ BM samples collected at diagnosis from a "test set" of 80 patients. The QDA statistical approach was employed to analyze the real-time expression results. We found that the eight-gene predictor set allowed to correctly predict the response to TD induction therapy in 57 out of the 80 cases analyzed (71 %).
In details, on the basis of real-time expression results, 36 out of 80 patients were predicted to be responders (CR) to TD, whereas the remaining 44 were predicted to be nonresponders (NR). Of the 36 CR-predicted patients, 16 were "true positive" since they actually achieved at least a nCR, while 20 who actually failed nCR plus CR were "false positive." Out of 44 NR-predicted patients, 41 were "true negative," whereas the remaining 3 were "false negative" since they actually achieved at least a nCR ( Table 3 ). The sensitivity of the eight-gene signature in predicting highquality response to TD induction therapy was 84 %, while the specificity of the assay was 67 % ( Table 3 ).
The eight-gene GEP signature predicts the clinical outcome after ASCT The outcome after autotransplantation(s) for the whole series of 80 patients who were included in the present study was analyzed according to real-time expression results at the time of diagnosis. On an intention-to-treat basis, the rate of CR, either immunofixation negative or positive, among the 36 patients who were predicted as responders to TD induction therapy was 50 %. The corresponding value in the subgroup of 44 NR-predicted patients was 23 % (P=0.001). Curves of OS, TTP, and EFS for these two subgroups of patients are shown in Fig. 1 . Briefly, the 65-month probability of OS for CR-predicted patients was 72 % as compared to 41 % for those who were predicted to be NR (P=0.03). The projected rates of TTP and EFS at 55 months for CR-predicted and NR-predicted patients were 69 vs. 34 % (P=0.003) and 55 vs. 19 % (P=0.01), respectively (Fig. 1) .
Subsequently, we analyzed the outcome of the 61 patients who actually failed at least nCR to TD induction therapy. Of these, 20 patients were incorrectly predicted as responders. Their probability to actually achieve at least nCR after ASCT(s) was 45 %, a value significantly higher than that observed among the subgroup of 41 correctly NR-predicted to TD (9.7 %; P=0.005; Tables 4 and 5) . Similarly, postautotransplantation OS for incorrectly CR-predicted patients was longer than that observed among correctly NR-predicted patients (median, not reached vs. 49 months, respectively; P=0.08; Fig. 2) . Interestingly, analysis of the real-time data of this subgroup of 20 incorrectly CRpredicted patients showed an expression pattern of the signature genes which was very similar to that found among the 16 correctly CR-predicted patients. (Supplementary  Fig. S3 ).
Discussion
In this study, the retrospective application of a pharmacoge nomic approach led to the development of an eight-gene GEP signature that correctly predicted high-quality response to TD induction therapy in 71 % of patients. Importantly, real-time expression results obtained at the time of diagnosis also NPV negative predictive value, PPV positive predictive value, CR immunofixation negative or positive complete response, NPV negative predictive value, NR failure to achieve immunofixation negative or positive complete response, PPV positive predictive value, TD thalidomidedexamethasone 
(C)
Time (months) Probability of progression (%) Fig. 1 Post autotransplantation(s) clinical outcomes for 80 patients stratified in CR-predicted and NR-predicted to TD induction therapy, according to the eight-gene signature at diagnosis. a Median OS for CR-predicted patients was not reached vs. 51 months for NR-predicted patients (P=0.03). b Median EFS for CR-predicted and NR-predicted patients was not reached and 34 months, respectively (P=0.01). c Median TTP for CR-predicted and NR-predicted patients was not reached and 38 months, respectively (P=0.03) correlated with post-autotransplantation rate of CR, TTP, EFS, and OS, thus providing a genomic classifier of clinical outcome after the entire treatment program comprising of TD induction therapy and subsequent autotransplantation(s).
The panel of cases herein described was sufficient to demonstrate the distinctive tracts of the molecular signature of patients who actually responded (≥nCR) to TD induction therapy. In fact, in both the training and the validation test sets, the gene profile of analyzed patients clearly clustered, suggesting the expression at diagnosis of common genetic pathways. By the opposite, patients who failed high-quality response to induction therapy displayed a scattered gene expression profiles distribution. This finding may reflect the widespread range of different qualities of responses in the non-responding subgroup of patients, ranging from very good partial response (6.2 %) to partial response (37.5 %) or less than partial response (32.5 %).
The main objective of the study has been to select the nominally best predictor set with the least number of genes for independent validation in 80 MM patients. The expression of the eight-gene predictor set allowed the stratification of patients in two subgroups, namely NR-predicted and CRpredicted. Analysis of post-autotransplantation outcomes for these two subgroups showed a major benefit for those patients who were predicted as responders to TD. Indeed, the rate of CR for these patients was more than twofold increased in comparison with the subgroup of NR-predicted. Similarly, OS, TTP, and PFS were also significantly extended when compared with patients who were predicted as nonresponders. Although these findings may simply reflect the higher rate of at least nCR to TD induction therapy observed in the subgroup of CR-predicted patients (44 versus 7 % in NR-predicted), it is worthy of note that the subgroup of 20 incorrectly CR-predicted patients actually had a more favorable outcome when compared to that of correctly NRpredicted patients. These data may suggest that the expression of the eight-gene predictor set allows the identification at diagnosis of two subgroups of patients with a different clinical outcome when treated upfront with TD induction therapy and subsequent ASCT(s).
Molecular genetic testing in MM patients at diagnosis is essential in the context of clinical trials, in order to identify strong prognostic markers associated with response to therapy and favorable clinical outcomes. The most promising approach to use microarray-based gene signatures to develop predictive classifiers of response to therapy in MM was previously reported by Mulligan and colleagues [34] . Several gene classifiers based on bone marrow plasma cells obtained from relapsed or refractory MM patients enrolled in phase 2 and phase 3 clinical trials with bortezomib allowed a response prediction with a test accuracy ranging from 55 to 70 %. In our study, the overall accuracy of the test was 71 %.
An overview of the 157 probe sets significantly associated with response to TD may reveal important insights into Patients were stratified into two subgroups (e.g., CR-predicted and NR-predicted) according to real-time expression results at diagnosis CR immunofixation negative or positive complete response, NR failure to achieve immunofixation negative or positive complete response, TD thalidomide-dexamethasone Time (months) Probability of overall survival (%) Fig. 2 Post-autotransplantation(s) overall survival curves for the subgroup of 61 patients who actually failed at least nCR to TD induction therapy. Patients were stratified in CR-predicted and NR-predicted to TD induction therapy, according to the eight-gene signature at diagnosis. Median OS for CR-predicted patients was not reached vs. 49 months for NR-predicted patients (P=0.08) the biological basis and molecular mechanisms associated with different responses to a particular therapy. For example, we were able to show that several genes differentially expressed at diagnosis by patients responding to TD are significantly involved in signaling pathways (selected by DAVID tool, among the Kegg pathways database) targeted by thalidomide and/or dexamethasone. In particular, signaling pathways which might be affected by the deregulated expression of genes in patients responding to TD are the MAPK signaling pathway (Ppp3r1, PRKY, PRKX, FAS, ATF2, MAP4K3, and DUSP4), the Wnt signaling pathway (Ppp3r1, PRKY, PRKX, and CCND2) and the p53 pathway (CCND2, FAS, CCNDE, and MDM4). These data suggest a pre-existing behavior of the neoplastic clone in TD responding patients to inhibit cell proliferation and to induce apoptosis.
It remains unclear whether the downregulation of the eight-gene set is a causal event in determining a particular phenotype, or if the set is merely a marker of a phenotype. It is interesting that the eight-gene signature includes genes already known to be involved in MM biology, (i.e., CCND2, CFLAR, WHSC1, and HSPA1A); nevertheless, whereas the role of CCND2 and CFLAR has been extensively studied and could be explained in MM in the context of well-known pathways [27, 28, 35, 36] , the roles of other genes like WHSC1 and HSPA1A are less clear. HSPA1A is a member of the HSP70 family of protein, proven to be a key modulator of the BM microenvironment [37] . Indeed, the inhibition of this heat-shock protein in vitro directly caused a reduced adhesion of MM cells to stromal cells and their consequent apoptosis, suggesting that HSPA1A might be involved in MM cell drug resistance [37] . WHSC1, also known as MMSET or NSD2, is involved in the t(4;14)(p16; q32) translocation, described in almost 20 % of MM patients at diagnosis [38] [39] [40] ; there are several reports examining the role of this protein in MM pathogenesis, as it contains known domains (a SET domain, found in many histone methyltransferases, nuclear localization signals, high mobility group box, and plant domain zinc-fingers) suggestive of a transcriptional cofactor, or direct and/or indirect modifier of chromatin [41, 42] .
The expression of ATF4, DDX17, RIT1, and RNF148 has not yet been linked to MM biology, but they do play critical roles in overall cellular biology, suggesting possible involvement in MM pathogenesis. Indeed, ATF4, which is one of the most significantly downregulated genes in responding patients, is a DNA-binding protein that belongs to the bZIP family of transcription factors, which plays a diverse role in gene regulation in mammalian cells. In a similar way, DDX17 (DEAD box polypeptide 17), also known as p72, has been shown to be a transcriptional coregulator of other transcription factors, among which are p53 and Runx2 [43] .
Taken together, these observations suggest that the eight genes identified in this analysis may not only be useful for clinical practice but may also provide further insight into the mechanisms underlying the sensitivity of MM patients to specific drug combination therapy. Additional work should be performed to investigate the possible pathways modulated by the concerted downregulation of these eight genes, as well as the possible mechanisms leading to the concomitant downregulation of these genes in subgroups of patients.
In conclusion, our study provides a predictive GEP signature, consisting of eight genes, which can be considered a clinical tool to predict the benefit of TD induction therapy for each individual patient. These data support the idea of clustering patients on the basis of their genetic background, in order to precisely identify the most appropriate individualized therapy. Moreover, genes differentially expressed in responding vs. non-responding patients provide a molecular basis to investigate new aspects of MM biology in the setting of drug combination therapy and targeted agents.
